LIVIVO - Search results -

Search results

Result 1 - 10 of total 85

Search options

Article: Cognitive rehabilitation of schizophrenia.

Hogarty, G E

2000 Volume 17, Issue 2, Page(s) 4–6

MeSH term(s)	Cognition ; Cognitive Therapy/methods ; Humans ; Schizophrenia/rehabilitation ; Schizophrenia/therapy ; Schizophrenic Psychology ; Secondary Prevention ; Social Adjustment
Language	English
Publishing date	2000-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	1326599-4
ISSN	1057-5022 ; 0884-3783
ISSN	1057-5022 ; 0884-3783
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6086: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.

Bielamowicz, Kevin / Dimitrion, Peter / Abla, Oussama / Bomken, Simon / Campbell, Patrick / Collin, Matthew / Degar, Barbara / Diamond, Eli L / Eckstein, Olive S / El-Mallawany, Nader / Fluchel, Mark / Goyal, Gaurav / Henry, Michael M / Hermiston, Michelle / Hogarty, Michael / Jeng, Michael / Jubran, Rima / Lubega, Joseph / Kumar, Ashish /

Ladisch, Stephan / McClain, Kenneth L / Merad, Miriam / Mi, Qing-Sheng / Parsons, D Williams / Peckham-Gregory, Erin / Picarsic, Jennifer / Prudowsky, Zachary D / Rollins, Barrett J / Shaw, Peter H / Wistinghausen, Birte / Rodriguez-Galindo, Carlos / Allen, Carl E

Cancer

2024

Abstract: Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical ... ...

Abstract	Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations range from single lesions with minimal impact to life-threatening disseminated disease. Therapy for systemic LCH has been established through serial trials empirically testing different chemotherapy agents and durations of therapy. However, fewer than 50% of patients who have disseminated disease are cured with the current standard-of-care vinblastine/prednisone/(mercaptopurine), and treatment failure is associated with long-term morbidity, including the risk of LCH-associated neurodegeneration. Historically, the nature of LCH-whether a reactive condition versus a neoplastic/malignant condition-was uncertain. Over the past 15 years, seminal discoveries have broadly defined LCH pathogenesis; specifically, activating mitogen-activated protein kinase pathway mutations (most frequently, BRAFV600E) in myeloid precursors drive lesion formation. LCH therefore is a clonal neoplastic disorder, although secondary inflammatory features contribute to the disease. These paradigm-changing insights offer a promise of rational cures for patients based on individual mutations, clonal reservoirs, and extent of disease. However, the pace of clinical trial development behind lags the kinetics of translational discovery. In this review, the authors discuss the current understanding of LCH biology, clinical characteristics, therapeutic strategies, and opportunities to improve outcomes for every patient through coordinated agent prioritization and clinical trial efforts.
Language	English
Publishing date	2024-04-30
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.35301
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.

Evageliou, Nicholas F / Hogarty, Michael D

Clinical cancer research : an official journal of the American Association for Cancer Research

2009 Volume 15, Issue 19, Page(s) 5956–5961

Abstract: ... the expansion of intracellular polyamine pools. Selective inhibition of key enzymes in this pathway, e.g., using ...

Abstract	MYC genes are deregulated in a plurality of human cancers. Through direct and indirect mechanisms, the MYC network regulates the expression of > 15% of the human genome, including both protein-coding and noncoding RNAs. This complexity has complicated efforts to define the principal pathways mediating MYC's oncogenic activity. MYC plays a central role in providing for the bioenergetic and biomass needs of proliferating cells, and polyamines are essential cell constituents supporting many of these functions. The rate-limiting enzyme in polyamine biosynthesis, ODC, is a bona fide MYC target, as are other regulatory enzymes in this pathway. A wealth of data link enhanced polyamine biosynthesis to cancer progression, and polyamine depletion may limit the malignant transformation of preneoplastic lesions. Studies with transgenic cancer models also support the finding that the effect of MYC on tumor initiation and progression can be attenuated through the repression of polyamine production. High-risk neuroblastomas (an often lethal embryonal tumor in which MYC activation is paramount) deregulate numerous polyamine enzymes to promote the expansion of intracellular polyamine pools. Selective inhibition of key enzymes in this pathway, e.g., using DFMO and/or SAM486, reduces tumorigenesis and synergizes with chemotherapy to regress tumors in preclinical models. Here, we review the potential clinical application of these and additional polyamine depletion agents to neuroblastoma and other advanced cancers in which MYC is operative.
MeSH term(s)	Animals ; Antineoplastic Agents/therapeutic use ; Drug Delivery Systems/methods ; Gene Expression Regulation, Neoplastic ; Genes, myc/physiology ; Homeostasis/drug effects ; Humans ; Mice ; Mice, Transgenic ; Models, Biological ; Neuroblastoma/drug therapy ; Neuroblastoma/genetics ; Neuroblastoma/metabolism ; Polyamines/metabolism
Chemical Substances	Antineoplastic Agents ; Polyamines
Language	English
Publishing date	2009-09-29
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-08-3213
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

Sokol, Elizabeth / Desai, Ami V / Applebaum, Mark A / Valteau-Couanet, Dominique / Park, Julie R / Pearson, Andrew D J / Schleiermacher, Gudrun / Irwin, Meredith S / Hogarty, Michael / Naranjo, Arlene / Volchenboum, Samuel / Cohn, Susan L / London, Wendy B

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2020 Volume 38, Issue 17, Page(s) 1906–1918

Abstract: Purpose: The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology ... ...

Abstract	Purpose: The Children's Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Classification (INPC) criteria. By definition, this leads to a duplication of the prognostic contribution of age. The individual histologic features underlying the INPC have prognostic strength and are incorporated in the International Neuroblastoma Risk Group classification schema. Here, we analyzed data in the International Neuroblastoma Risk Group Data Commons to validate the prognostic strength of the underlying INPC criteria and to determine whether a risk classification devoid of the confounding of age and INPC criteria will identify new prognostic subgroups. Patients and methods: Event-free survival of patients diagnosed between 1990 and 2002 (cohort 1; n = 10,104) and between 2003 and 2016 (cohort 2; n = 8,761) was analyzed. Recursive partitioning with univariate Cox models of event-free survival ("survival tree regression") was performed using (1) individual INPC criteria (age at diagnosis, histologic category, mitosis-karyorrhexis index (MKI), grade of differentiation) and (2) factors in (1) plus other COG-risk biomarkers (International Neuroblastoma Staging System [INSS] stage, Results: The independent prognostic ability of age, histologic category, MKI, and grade were validated. Four histologic prognostic groups were identified (< 18 months with low Conclusion: Replacing INPC with individual histologic features in the COG risk classification will eliminate confounding, facilitate international harmonization of risk classification, and provide a schema for more precise prognostication and refined therapeutic approaches.
MeSH term(s)	Adolescent ; Age Factors ; Biomarkers, Tumor ; Child ; Child, Preschool ; Cohort Studies ; Humans ; Infant ; Mitotic Index ; Neoplasm Grading ; Neuroblastoma/classification ; Neuroblastoma/diagnosis ; Neuroblastoma/pathology ; Prognosis ; Young Adult
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2020-04-21
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.19.03285
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reply to K. Beiske et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2020 Volume 38, Issue 31, Page(s) 3720–3721

MeSH term(s)	Humans ; Mitosis ; Neuroblastoma ; Prognosis
Language	English
Publishing date	2020-09-15
Publishing country	United States
Document type	Letter ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.20.02147
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell, Kevin / Naranjo, Arlene / Hibbitts, Emily / Gastier-Foster, Julie M / Bagatell, Rochelle / Irwin, Meredith S / Shimada, Hiroyuki / Hogarty, Michael / Park, Julie R / DuBois, Steven G

European journal of cancer (Oxford, England : 1990)

2020 Volume 133, Page(s) 112–119

Abstract: Purpose: MYCN amplification (MNA) is associated with poor outcomes in neuroblastoma. Less is known about heterogeneous MNA within a tumour. We compared clinical characteristics, biologic features and clinical outcomes of patients with heterogeneous MNA ... ...

Abstract	Purpose: MYCN amplification (MNA) is associated with poor outcomes in neuroblastoma. Less is known about heterogeneous MNA within a tumour. We compared clinical characteristics, biologic features and clinical outcomes of patients with heterogeneous MNA to patients with either homogeneous MNA or MYCN wild-type tumours. Patients and methods: In this retrospective cohort study, we categorized patients as having tumours with MYCN wild-type, homogeneous MNA (>20% amplified tumour cells) or heterogeneous MNA (≤20% amplified tumour cells). We used chi-squared or Fisher's exact tests to compare features between groups. We used log-rank tests and Cox models to compare event-free survival (EFS) and overall survival (OS) between groups. Results: MYCN status and heterogeneity status (if amplified) could be ascertained in diagnostic tumour samples from 5975 patients, including 57 (1%) with heterogeneous MNA, 981 (16.4%) with homogeneous MNA, and 4937 (82.6%) with MYCN wild-type tumours. Multiple clinical and biological features differed between patients with heterogeneous vs. homogeneous MNA, including enrichment for thoracic primary sites and paucity of 1p loss of heterozygosity with heterogeneous MNA (p < 0.0001). Importantly, EFS and OS were not significantly different between patients with heterogeneous vs. homogeneous MNA. Further, EFS and OS for patients with heterogeneous MNA were significantly inferior to patients with wild-type MYCN. Conclusion: Although neuroblastomas with heterogeneous MNA demonstrate significantly different biological and clinical patterns compared with homogeneous MNA, prognosis is similar between the two groups. These results support current practice that treats patients with heterogeneous MNA similarly to patients with homogeneous MNA.
MeSH term(s)	Child ; Child, Preschool ; Cohort Studies ; Female ; Gene Amplification ; Genetic Association Studies ; Genetic Heterogeneity ; Humans ; Infant ; Male ; N-Myc Proto-Oncogene Protein/genetics ; Neuroblastoma/diagnosis ; Neuroblastoma/genetics ; Neuroblastoma/mortality ; Prognosis ; Retrospective Studies ; Survival Analysis
Chemical Substances	MYCN protein, human ; N-Myc Proto-Oncogene Protein
Language	English
Publishing date	2020-05-31
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2020.04.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.

The EMBO journal

2022 Volume 41, Issue 8, Page(s) e108272

Abstract: Most cancer deaths result from progression of therapy resistant disease, yet our understanding of this phenotype is limited. Cancer therapies generate stress signals that act upon mitochondria to initiate apoptosis. Mitochondria isolated from ... ...

Abstract	Most cancer deaths result from progression of therapy resistant disease, yet our understanding of this phenotype is limited. Cancer therapies generate stress signals that act upon mitochondria to initiate apoptosis. Mitochondria isolated from neuroblastoma cells were exposed to tBid or Bim, death effectors activated by therapeutic stress. Multidrug-resistant tumor cells obtained from children at relapse had markedly attenuated Bak and Bax oligomerization and cytochrome c release (surrogates for apoptotic commitment) in comparison with patient-matched tumor cells obtained at diagnosis. Electron microscopy identified reduced ER-mitochondria-associated membranes (MAMs; ER-mitochondria contacts, ERMCs) in therapy-resistant cells, and genetically or biochemically reducing MAMs in therapy-sensitive tumors phenocopied resistance. MAMs serve as platforms to transfer Ca
MeSH term(s)	Apoptosis ; Ceramides ; Drug Resistance, Multiple ; Humans ; Mitochondria ; Mitochondrial Membranes ; Neuroblastoma/drug therapy
Chemical Substances	Ceramides
Language	English
Publishing date	2022-02-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	586044-1
ISSN	1460-2075 ; 0261-4189
ISSN (online)	1460-2075
ISSN	0261-4189
DOI	10.15252/embj.2021108272
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1808: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 100: Show issues

Order via subito

Details ▾

Article: Prevention of relapse in chronic schizophrenic patients.

Hogarty, G E

The Journal of clinical psychiatry

1993 Volume 54 Suppl, Page(s) 18–23

Abstract: New treatments offer hope for a reduction in the rate of relapse among chronic schizophrenic patients. The control of factors such as drug noncompliance, the dose of neuroleptic drug, the level of stimulation in the patient's therapeutic and home ... ...

Abstract	New treatments offer hope for a reduction in the rate of relapse among chronic schizophrenic patients. The control of factors such as drug noncompliance, the dose of neuroleptic drug, the level of stimulation in the patient's therapeutic and home environments, extrapyramidal side effects, attention and arousal deficits, and the stresses of everyday life events can reduce the rate of relapse in most patients. A relapse rate of 65% to 70% in the first year following hospital discharge can be reduced to 40% with the use of antipsychotic medication and can be further reduced to less than 20% with the addition of psychosocial therapy. Low doses of antipsychotic drugs combined with psychosocial treatment can have an added positive impact on the quality of life as well.
MeSH term(s)	Antipsychotic Agents/therapeutic use ; Behavior Therapy ; Chronic Disease ; Combined Modality Therapy ; Drug Administration Schedule ; Family Therapy ; Female ; Humans ; Male ; Quality of Life ; Recurrence ; Schizophrenia/drug therapy ; Schizophrenia/prevention & control ; Schizophrenic Psychology
Chemical Substances	Antipsychotic Agents
Language	English
Publishing date	1993-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	716287-x
ISSN	1555-2101 ; 0160-6689
ISSN (online)	1555-2101
ISSN	0160-6689
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 108: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 247: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency.

Pediatric research

2020 Volume 88, Issue 2, Page(s) 163–167

MeSH term(s)	Career Choice ; Child ; Financing, Government ; Hospitals, Pediatric/organization & administration ; Humans ; Internship and Residency ; Mentors ; National Institutes of Health (U.S.) ; Pediatricians ; Pediatrics/education ; Pediatrics/organization & administration ; Research Support as Topic ; Training Support/organization & administration ; Translational Research, Biomedical/education ; United States
Language	English
Publishing date	2020-03-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	4411-8
ISSN	1530-0447 ; 0031-3998
ISSN (online)	1530-0447
ISSN	0031-3998
DOI	10.1038/s41390-020-0837-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 564: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 373: Show issues

Order via subito

Details ▾

Article ; Online: Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Go, Ronald S / Jacobsen, Eric / Baiocchi, Robert / Buhtoiarov, Ilia / Butler, Erin B / Campbell, Patrick K / Coulter, Don W / Diamond, Eli / Flagg, Aron / Goodman, Aaron M / Goyal, Gaurav / Gratzinger, Dita / Hendrie, Paul C / Higman, Meghan / Hogarty, Michael D / Janku, Filip / Karmali, Reem / Morgan, David / Raldow, Anne C /

Stefanovic, Alexandra / Tantravahi, Srinivas K / Walkovich, Kelly / Zhang, Ling / Bergman, Mary Anne / Darlow, Susan D

Journal of the National Comprehensive Cancer Network : JNCCN

2021 Volume 19, Issue 11, Page(s) 1277–1303

Abstract: Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal ...

Abstract	Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
MeSH term(s)	Adult ; Erdheim-Chester Disease/drug therapy ; Hematologic Neoplasms ; Histiocytosis, Langerhans-Cell/diagnosis ; Histiocytosis, Langerhans-Cell/drug therapy ; Histiocytosis, Langerhans-Cell/pathology ; Histiocytosis, Sinus/diagnosis ; Histiocytosis, Sinus/drug therapy ; Histiocytosis, Sinus/pathology ; Humans ; Prognosis
Language	English
Publishing date	2021-11-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	2250759-0
ISSN	1540-1413 ; 1540-1405
ISSN (online)	1540-1413
ISSN	1540-1405
DOI	10.6004/jnccn.2021.0053
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito